NASDAQ$ELVN
Enliven Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Enliven Therapeutics reported Q1 2025 a net loss of $28.5M, diluted EPS of $-0.57.
For Q1 2025, Enliven Therapeutics reported net loss was $28.5M, diluted EPS was $-0.57. The quarterly filing discusses operating priorities, liquidity, and sector-specific risks in MD&A.
- Net loss $28.5M.
- Diluted EPS $-0.57.
- MD&A highlights cash runway, pipeline progress, and macro risks.
Headline financials
Revenue & EPS history
Enliven Therapeutics · Revenue · Quarterly
$0
Forward guidance
Outlook emphasizes clinical milestones, cash runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership optionality.
- Cost controls and balance-sheet flexibility.
Headwinds
- Operating losses until commercialization.
- Trial timing and regulatory uncertainty.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.4%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+7.4%
Avg return
30 days after
48%
11 / 23 earnings
Positive
+17.6%
Q2 2020
Best reaction
-22.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +4.3% | +3.4% | +35.1% | |
| Q3 2025 | -0.3% | +11.3% | -16.9% | |
| Q2 2025 | -0.8% | -1.1% | -0.1% | |
| Q1 2025 | +0.4% | +19.7% | +29.3% | |
| Q4 2024 | -3.5% | -7.7% | -14.6% | |
| Q3 2024 | -8.3% | -8.4% | -14.8% | |
| Q1 2024 | -2.0% | -5.9% | -10.1% | |
| Q4 2023 | -2.4% | +43.0% | +71.8% | |
| Q3 2023 | -9.3% | -12.4% | -4.5% | |
| Q2 2023 | -2.0% | -8.0% | -7.1% | |
| Q1 2023 | -2.4% | -0.3% | +8.8% | |
| Q4 2022 | +2.1% | +4.5% | +2.6% | |
| Q3 2022 | +0.4% | -5.5% | -1.3% | |
| Q2 2022 | +2.5% | -1.7% | -3.4% | |
| Q1 2022 | -6.1% | -11.5% | -12.2% | |
| Q4 2021 | +11.1% | +22.2% | -27.8% | |
| Q3 2021 | +0.8% | -3.8% | -20.2% | |
| Q2 2021 | +0.3% | -18.0% | -14.5% | |
| Q1 2021 | +12.8% | +15.8% | +27.3% | |
| Q4 2020 | -22.5% | -19.5% | -31.7% | |
| Q3 2020 | -3.4% | +13.9% | +57.0% | |
| Q2 2020 | +17.6% | +19.8% | +8.1% | |
| Q1 2020 | +1.1% | +4.4% | +108.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro